Pharma Focus Asia

Galderma Has Received Regulatory Approval for Restylane® SHAYPE™, a Novel Hyaluronic Acid Injectable Designed for Enhancing the Chin Region

Monday, January 22, 2024

Galderma, a leading player in the dermatology industry, has recently obtained approval from Health Canada for its latest hyaluronic acid (HA) injectable, Restylane® SHAYPE™. This innovative product is specifically designed for temporary chin augmentation, addressing concerns related to chin definition and facial balance. The approval paves the way for the availability of Restylane® SHAYPE™ in Canada starting February 2024.

The chin is a critical aspect of overall facial appearance, influencing factors such as facial proportions, profile, and shape. Genetic factors and the aging process can impact chin definition, resulting in issues such as a double chin or a "weak chin." Traditionally, surgical implants have been the conventional solution for enhancing lower face structure, with limited non-surgical alternatives.

Restylane® SHAYPE™, powered by Galderma's new NASHA HD™ technology, features the highest G' ("G prime") in the Restylane® range. As the firmest HA gel currently available, it enables aesthetic injectors to shape, project, and elongate the chin for natural-looking results from any angle. Notably, Restylane® SHAYPE™ is minimally modified, closely resembling the natural HA found in the skin, and can be easily reversed.

In a pivotal 12-month study conducted at multiple sites in Canada, 91% of patients reported sustained aesthetic improvements, with 84% expressing willingness to undergo Restylane® SHAYPE™ treatment again. Impressively, up to 97% of patients would recommend the treatment to others, and 95% felt that their results appeared natural.

Dr. Baldo Scassellati Sforzolini, Global Head of R&D at Galderma, emphasized that Restylane® SHAYPE™ represents the next generation in HA, surpassing existing options for chin augmentation. The product's unique ability to create a bone-mimicking effect makes it an ideal choice for lower face shaping, providing long-lasting, natural-looking results for up to 12 months without the need for retreatment.

Dr. Andreas Nikolis, Principal Investigator of the Restylane® SHAYPE™ pivotal study, noted the significant demand for a product capable of mimicking bone effects without surgical downtime. Galderma's meticulous clinical evaluation has resulted in the development of a safe and effective HA injectable for chin remodeling.

Galderma is actively pursuing regulatory approvals in other countries, with the goal of introducing this groundbreaking innovation to a global audience. The RESTYLANE® portfolio, produced using NASHA HD™ technology, represents over 27 years of clinical experience and has been utilized in over 65 million treatments worldwide, making it the most diverse range of fillers for various aesthetic needs.



magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024